Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide

Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide

Glioblastoma (GBM) is often treated with the cytotoxic drug temozolomide, but the disease inevitably recurs in a drug-resistant form after initial treatment. Here, we report that in GBM cells, even a modest decrease in the mismatch repair (MMR) components MSH2 and MSH6 have profound effects on temoz...

Full description

Bibliographic Details
Main Authors: Sangaraju, D., Tretyakova, N., McFaline, Jose Luis, Stanciu, Monica, Nagel, Zachary D., Mazzucato, Patrizia, Cerniauskas, Edvinas, Barford, Kelly, Vargas, Amanda, Chen, Yimin, Lees, Jacqueline, Hemann, Michael, Samson, Leona D, Braun, Christian Joerg, White, Forest M.
Other Authors: Massachusetts Institute of Technology. Center for Environmental Health Sciences
Format: Article
Language:en_US
Published: American Association for Cancer Research 2017
Online Access:http://hdl.handle.net/1721.1/106346
https://orcid.org/0000-0002-5229-8748
https://orcid.org/0000-0002-7221-6041
https://orcid.org/0000-0001-9451-2194
https://orcid.org/0000-0002-1545-1651
https://orcid.org/0000-0002-7112-1454

Internet

http://hdl.handle.net/1721.1/106346
https://orcid.org/0000-0002-5229-8748
https://orcid.org/0000-0002-7221-6041
https://orcid.org/0000-0001-9451-2194
https://orcid.org/0000-0002-1545-1651
https://orcid.org/0000-0002-7112-1454

Similar Items